Genetic medicine company LogicBio Therapeutics (Nasdaq: LOGC) lost 55% of its stock market value on Wednesday.
The US company had earlier provided an update on the LB-001 clinical development program, namely that the US Food and Drug Administration (FDA) has told LogicBio that its Phase I/II SUNRISE trial of LB-001 in pediatric patients with methylmalonic acidemia has been placed on clinical hold.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze